Assistant Professor TAKAHASHI Daiki
| Campus | Katahira campus |
|---|---|
| Laboratory |
Analytical Bioorganic Chemistry
|
| Tel | +81-22-217-6203 |
| daiki.takahashi.d4＠tohoku.ac.jp | |
| Website | https://www.agri.tohoku.ac.jp/bunseki/index-j.html |
| Career |
Education: B.S. Faculty of Agriculture and Life Science, Hirosaki University (2013), Graduate School of Life Sciences, Tohoku University (2019, PhD)
Research Experience: Assis. Prof., Tohoku University (2020-) |
|---|---|
| Selected Publications |
p62 Phase-Separation as the Foundation of Autophagy-Based Degraders.
Daiki Takahashi, Hirokazu Arimoto Biochemistry 62 559-560 (2022) Selective autophagy as the basis of autophagy-based degraders.
Daiki Takahashi, Hirokazu Arimoto Cell Chem. Biol. 28 1061-1071 (2021) Targeting selective autophagy by AUTAC degraders.
Daiki Takahashi, Hirokazu Arimoto Autophagy 16 765-766 (2020) AUTACs: Cargo-Specific Degraders Using Selective Autophagy.
Daiki Takahashi, Jun Moriyama, Tomoe Nakamura, Erika Miki, Eriko Takahashi, Ayami Sato, Takaaki Akaike, Kaori Itto-Nakama, Hirokazu Arimoto Molecular Cell 76 797-810 (2019) 8-Nitro-cGMP: A Novel Protein-Reactive cNMP and Its Emerging Roles in Autophagy.
Daiki Takahashi, Hirokazu Arimoto Handb. Exp. Pharmacol. 238 253-268 (2017) |
| Activities in Academic Societies |
Memberships: The Chemical Society of Japan, Japanese Society for Chemical Biology, The Japanese Biochemical Society
|
| Teaching |
Laboratory experiment
|
Recent Activities
1. AUTACs: cargo-specific degraders using selective autophagy
Clinical drugs in use today are small molecule inhibitors of disease-related molecules. In contrast, a method that removes (degrades) these molecules is a fundamental therapy. We have developed a compound (AUTAC: autophagy-targeting chimera) that induces targeted degradation of disease-related proteins or organelles via autophagy. AUTAC is the first drug that degrades organelles. Our research is attracting attention from pharmaceutical industry worldwide.
Clinical drugs in use today are small molecule inhibitors of disease-related molecules. In contrast, a method that removes (degrades) these molecules is a fundamental therapy. We have developed a compound (AUTAC: autophagy-targeting chimera) that induces targeted degradation of disease-related proteins or organelles via autophagy. AUTAC is the first drug that degrades organelles. Our research is attracting attention from pharmaceutical industry worldwide.
2. Elucidation of the mechanism of substrate-specific autophagy
AUTAC is designed based on "S-guanylation" a marker of autophagic degradation. However, it is not clear how AUTAC induces autophagy. Therefore, we are working to elucidate this mechanism using chemical biology methods. It is very exciting to unravel new mechanisms that support biological activities, and we believe that we can create the next generation of AUTAC based on these new mechanisms.